Income statement
USD
Annual
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Revenue | 18M | 17M | 20M | 19M | 23M |
| Gross Profit | 4M | 7M | 9M | 8M | 11M |
| Operating Income | -21M | -13M | -8M | -8M | -6M |
| EBITDA | -20M | -13M | -8M | -7M | -5M |
| Net Income | -20M | -14M | -7M | -7M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Response Genetics, Inc (RGDXQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +7.9%, EPS growth of -48.6%, a dividend yield of 0.0%. What stands out right now is revenue +7.9%, EPS -48.6%, free cash flow -2.4% with operating margin -118.5% and ROIC -49.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RGDXQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGDXQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGDXQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGDXQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$22.6M
+20.8% YoY
FY Net Income
-$5.7M
+22.4% YoY
Free Cash Flow
-$5.5M
+38.9% YoY
Revenue Growth
+7.9%
EPS Growth
-48.6%
Gross Margin
21.9%
Net Margin
-111.9%
Income statement
USD
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Revenue | 18M | 17M | 20M | 19M | 23M |
| Gross Profit | 4M | 7M | 9M | 8M | 11M |
| Operating Income | -21M | -13M | -8M | -8M | -6M |
| EBITDA | -20M | -13M | -8M | -7M | -5M |
| Net Income | -20M | -14M | -7M | -7M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Cash & Equivalents | 19M | 2M | 8M | 9M | 2M |
| Total Assets | 49M | 13M | 18M | 17M | 8M |
| Total Liabilities | 16M | 15M | 12M | 17M | 14M |
| Shareholder Equity | 33M | -1M | 6M | -542K | -6M |
| Total Debt | 6M | 10M | 1M | 1M | 1M |
| Net Debt | -13M | 7M | -7M | -8M | -310K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+36.5% YoY
Capital Expenditures
391K
+59.1% YoY
Free Cash Flow
5M
+38.9% YoY
Key ratios
Gross Margin
21.9%
Operating Margin
-118.5%
Net Margin
-111.9%
ROE
-126.8%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.